Microarray Cross-platform Study

Laboratory products

Microarray Cross-platform Study

10 Jun, 2008

Published over 18 years ago. See the latest and most current information on Laboratory products.

Agilent Technologies Inc. has announced that the first objective comparison of its kind of tiling microarray array platforms using
engineered DNA targets demonstrated the high performance and cost effectiveness of Agilent microarrays.
Unlike previous evaluations, the composition of the spike-in DNA in this study was engineered to mimic chromatin immunoprecipitation (ChIP) or copy-number amplification experiments across a wide dynamic range. To ensure a fair evaluation, the composition was not disclosed to participants. This made it possible to quantitatively evaluate each platform’s sensitivity and specificity of detecting and quantifying a predefined standard without bias.
First, platforms were compared using their highest possible tiling density. In evaluating results from comparable algorithms, Agilent
consistently achieved the highest or equivalent scores, but did so with fewer probes, half as many replicates and less sample DNA than either of the other platforms.
Overall, the study found that longer oligonucleotide (60-nt) microarrays, such as Agilent’s, were more sensitive at detecting very low enrichment or copy number. Additionally, Agilent demonstrated the highest levels of sensitivity and specificity per probe, in some cases
by orders of magnitude, over a range of simulated tiling densities.

Latest News

Lab Asia 33.4 - August 2026

Explore our Digital Edition

Discover the latest news and research

Digital edition

Explore Our Other Sites

Envirotech Online
Designed for semiconductor. Proven across industries.
Explore more Arrow
Pollution Solutions Online
Oil pipeline decommissioning in Wales secures environmental safety for future generations
Explore more Arrow
Petro Online
Flash point testing aligned with petrochemical compliance requirements
Explore more Arrow
Chromatography Today
Unlock high-resolution analysis of therapeutic oligonucleotides
Explore more Arrow